Drugs / Ad26.RSV.FA2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02561871 | Sep 2015 → Sep 2016 | respiratory syncytial virus infectious disease | Crucell Holland BV | Completed | No outcome recorded |
| Phase 1 | NCT02440035 | Apr 2015 → Jun 2016 | — | Crucell Holland BV | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.RSV.FA2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02561871 ↗ |
| Modality | Vaccine | “human adenovirus-vectored vaccine candidate” NCT02561871 ↗ |
| Route | Intramuscular | “intramuscular injection of Ad26.RSV.FA2” NCT02440035 ↗ |